New Guidance for Treating Systemic Sclerosis-associated ILD
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
Category: Other Chronic Diseases
Other Chronic Diseases
Latest
Other Chronic Diseases
Latest
Gefapixant Gets European Medicines Agency’s Backing for Chronic Cough
Merck’s investigational drug for chronic cough is one step closer to coming to market after receiving a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Other Chronic Diseases
Latest
aTyr Announces Phase 2 Study of SSc-ILD Drug
The expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Age-related Macular Degeneration a Risk Factor for COVID-19 Infection, Mortality
Age-related macular degeneration (AMD) is a clinical risk factor for increased risk for COVID-19 infection and mortality.
Read More
Interstitial Lung Disease Common After COVID-19
Researchers estimated that up to 11% of hospitalized COVID-19 patients had interstitial lung disease after recovery from COVID.
Read More
Airway Protein May Be Key to Body’s Mucociliary Clearance
MUC5AC, an airway protein, plays an important (and overlooked) role in the body’s mucociliary clearance system, according to research published in Science Advances.
Read More
When to Leverage High Frequency Chest Wall Oscillation in Non-Cystic Fibrosis Bronchiectasis Patients
This article will present notable insights from a roundtable of pulmonologists who discuss potential solutions to improve treatment strategies for non-cystic fibrosis bronchiectasis patients.
Read More
Inhaled Nitric Oxide Delivery: Past, Present, and Future
Inhaled nitric oxide has been utilized as a pulmonary vasodilator for over 20 years and research is ongoing to uncover the usefulness of iNO in several lung diseases and disorders.
Read More
Zephyrx Joins ALS Research Study
Zephyrx, a leading provider of end-to-end remote respiratory monitoring, has joined forces with EverythingALS on a new study to find a diagnosis, treatment, and cure for Amyotrophic Lateral Sclerosis.
Read More
Prenatal Vitamin D, Fish Oil Supplements Lowered Risk of Croup
Babies and children under three years old are less likely to develop croup if their mothers took fish oil and vitamin D supplements during pregnancy, according to new results from a clinical trial.
Read More
SARS-CoV-2 Antigen Levels Linked to COVID Severity, Outcomes
The amount of SARS-CoV-2 antigen measured in the blood of patients hospitalized with COVID-19 is associated with illness severity and other clinical outcomes, according to a new study published in the Annals of Internal Medicine.
Read More
First Drug Approved for Acid Sphingomyelinase Deficiency
Genzyme’s Xenpozyme was approved for pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD) a rare genetic disease that causes premature death due to neurologic and respiratory complications.
Read More
Possible Therapeutic Target for ‘Sporadic’ ALS
Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS).
Read More
New ‘Breakthrough’ Therapy for Non-CF Bronchiectasis
The US FDA recently granted Breakthrough Therapy Designation to a novel inhaled therapy called CMS I-neb, which is designed to treat non-CF bronchiectasis.
Read More
ALS Action Plan to Address Neurodegenerative Diseases
The FDA unveiled an ALS Action Plan for Rare Neurodegenerative Diseases, a five-year strategy for improving and extending the lives of people living with rare neurodegenerative diseases.
Read More